CureVac (CVAC) Competitors $3.90 -0.38 (-8.88%) Closing price 04:00 PM EasternExtended Trading$3.94 +0.04 (+0.90%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. ZLAB, VKTX, CRNX, ALVO, SRRK, MRUS, ACAD, CPRX, MOR, and PTGXShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Zai Lab (ZLAB), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Scholar Rock (SRRK), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Zai Lab Viking Therapeutics Crinetics Pharmaceuticals Alvotech Scholar Rock Merus ACADIA Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics Zai Lab (NASDAQ:ZLAB) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Is ZLAB or CVAC more profitable? CureVac has a net margin of 20.72% compared to Zai Lab's net margin of -76.14%. CureVac's return on equity of 21.98% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-76.14% -36.97% -27.10% CureVac 20.72%21.98%15.72% Does the MarketBeat Community prefer ZLAB or CVAC? Zai Lab received 204 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 64.53% of users gave Zai Lab an outperform vote while only 56.25% of users gave CureVac an outperform vote. CompanyUnderperformOutperformZai LabOutperform Votes23164.53% Underperform Votes12735.47% CureVacOutperform Votes2756.25% Underperform Votes2143.75% Which has higher valuation & earnings, ZLAB or CVAC? CureVac has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$418.33M8.71-$334.62M-$2.49-13.26CureVac$535.18M1.78-$281.58M$0.825.19 Which has more risk & volatility, ZLAB or CVAC? Zai Lab has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Does the media prefer ZLAB or CVAC? In the previous week, Zai Lab had 9 more articles in the media than CureVac. MarketBeat recorded 13 mentions for Zai Lab and 4 mentions for CureVac. Zai Lab's average media sentiment score of 0.93 beat CureVac's score of 0.08 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ZLAB or CVAC? Zai Lab currently has a consensus price target of $47.37, suggesting a potential upside of 43.44%. CureVac has a consensus price target of $14.00, suggesting a potential upside of 229.02%. Given CureVac's stronger consensus rating and higher possible upside, analysts plainly believe CureVac is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75CureVac 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of ZLAB or CVAC? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.0% of Zai Lab shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryCureVac beats Zai Lab on 10 of the 18 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$942.44M$6.54B$5.40B$8.47BDividend YieldN/A2.66%5.22%4.11%P/E Ratio7.649.1226.7519.95Price / Sales1.78252.31393.46114.60Price / CashN/A65.8538.2534.62Price / Book1.706.486.834.58Net Income-$281.58M$143.78M$3.22B$248.19M7 Day Performance26.26%4.80%5.26%2.14%1 Month Performance32.55%9.37%13.27%16.20%1 Year Performance29.33%-1.19%17.58%7.87% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.7226 of 5 stars$3.90-8.9%$14.00+259.0%+25.9%$874.92M$535.18M7.09880News CoverageUpcoming EarningsGap DownZLABZai Lab2.6626 of 5 stars$29.40+0.5%$47.37+61.1%+56.6%$3.24B$418.33M-10.611,950VKTXViking Therapeutics4.4315 of 5 stars$28.30+2.7%$87.15+208.0%-57.5%$3.18BN/A-28.3020Positive NewsCRNXCrinetics Pharmaceuticals3.6819 of 5 stars$33.32+8.6%$73.00+119.1%-38.0%$3.12B$1.04M-8.93210Gap UpALVOAlvotech1.7714 of 5 stars$10.25+5.9%$18.00+75.6%-27.6%$3.09B$489.68M-5.544High Trading VolumeSRRKScholar Rock4.0186 of 5 stars$32.46+5.8%$42.67+31.4%+151.9%$3.08B$33.19M-13.81140Positive NewsEarnings ReportAnalyst RevisionGap UpMRUSMerus3.2438 of 5 stars$42.41+3.7%$85.15+100.8%+0.9%$2.94B$36.13M-10.7437Earnings ReportAnalyst ForecastACADACADIA Pharmaceuticals3.2836 of 5 stars$17.52+0.5%$24.70+41.0%+43.6%$2.93B$957.80M22.46510Trending NewsAnalyst ForecastAnalyst RevisionGap UpCPRXCatalyst Pharmaceuticals4.6121 of 5 stars$23.83+2.0%$32.29+35.5%+45.9%$2.91B$534.65M20.1980Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.405 of 5 stars$45.27+5.4%$65.44+44.6%+49.1%$2.80B$207.80M17.02120News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies ZLAB Competitors VKTX Competitors CRNX Competitors ALVO Competitors SRRK Competitors MRUS Competitors ACAD Competitors CPRX Competitors MOR Competitors PTGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
